GON Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Sustained Revenue RampA multi-year inflection in revenue and a 31% YoY Q1 increase indicate durable commercial adoption of RYTELO. Persistent top-line growth buttresses scale economies, funds continued R&D and commercialization, and improves the firm's ability to invest toward sustainable margins over 2–6 months.
Commercial Traction & Account ExpansionQuarterly demand growth and increasing prescribing accounts reflect expanding physician acceptance and deeper market penetration. These structural commercial gains support repeatable revenue streams, better forecasting, and higher long‑term uptake potential across treatment lines.
Balance Sheet CushionA meaningful equity cushion and manageable leverage provide financing flexibility while the company scales. This capital structure reduces immediate refinancing risk, enables continued commercial and clinical investment, and supports execution through upcoming milestones over the medium term.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flows signal the company is still consumption‑driven rather than self‑funding. Sustained cash burn requires either strong sustained revenue growth, further cost cuts, or external financing, all of which materially affect strategic flexibility over the coming months.
Widening Gross‑to‑Net PressureA structurally higher gross‑to‑net reduces realized revenue per unit and compresses margins even as volumes grow. Persistent 20%+ adjustments from payer mix and contracting materially erode cash conversion and make it harder to translate sales growth into durable profitability.
Clinical Outcome UncertaintyKey trial readouts are pivotal for label expansion, guideline uptake, and long‑term commercial trajectory. A negative or neutral interim could slow adoption and reduce upside across indications, altering revenue durability and the company’s ability to justify continued commercial investment.
Geron News
GON FAQ
What was Geron Corporation’s price range in the past 12 months?
Currently, no data Available
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is CHF738.66M.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 12 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on May 06, 2026. The company reported -$0.008 earnings per share for the quarter, beating the consensus estimate of -$0.016 by $0.008.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation does not currently pay dividends.
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corporation have?
Currently, no data Available
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -$0.008 in its last earnings report, beating expectations of -$0.016. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in CH:GON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GON Stock 12 Month Forecast
Average Price Target
$3.27